actin related protein 2/3 complex subunit 3 pseudogene 5Genealiases: []
Q-omics provides the consensus-scored ARPC3P5 profile across patient tissues and cancer cell-line models. ARPC3P5 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in CESC. Among the 18 cancer types available for tumor–normal comparison, ARPC3P5 is differentially expressed in 9, with the highest sampling consensus in THCA. Additionally, ARPC3P5 RNA expression shows 7,623 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight CESC, THCA, and LSCC as cancer lineages where ARPC3P5 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ARPC3P5 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ARPC3P5 survival associations across molecular data types. ARPC3P5 RNA expression shows survival associations in the most cancer types (23). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ARPC3P5 RNA expression–survival associations across cancer types. High ARPC3P5 expression shows unfavorable associations in LIHC, BRCA and LGG, but favorable associations in CESC, LUSC and SKCM. The CESC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify CESC as the clearest survival context for ARPC3P5 RNA expression.
This table summarizes ARPC3P5 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for ARPC3P5. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ARPC3P5 shows higher tumor expression in THCA, LUAD, COAD, BRCA, STAD and LUSC. The THCA box plot shows higher ARPC3P5 RNA expression in tumor versus normal tissue (log2 FC = +0.157, t-test p = .001).
This table shows molecular features associated with ARPC3P5 in patient tissues and cancer cell lines. In patient samples, ARPC3P5 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set.
